ArticleNucleic acids research2026
The molecular mechanisms of the ShosTA system in mediating anti-phage defense.
Article in Nucleic acids research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
The ShosTA system, a two-component toxin-antitoxin (TA) system consisting of the ShosT and ShosA proteins, has recently been shown to mediate anti-phage defense. However, the molecular mechanisms underlying this system's role in anti-phage defense remain elusive. Here, we first confirmed that ShosT functions as the toxic component that induces cell death, while ShosA acts as the antitoxin to neutralize these toxic effects. We then solved the crystal structures of apo-ShosT, ShosA, and the ShosT-PRPP (phosphoribosyl pyrophosphate) complex. The structural data reveal that while ShosT contains a PRTase (phosphoribosyl-transferase) domain, it possesses unique noncanonical features; furthermore, we demonstrate that its binding to PRPP is indispensable for its toxic activity. ShosA is a DprA-like protein that functions as a homodimer. Both its ssDNA-binding and dimerization abilities are essential for its antitoxin activity. Further biochemical and structural studies demonstrate that ShosA directly binds to RecA, an interaction that is essential for neutralizing ShosT. The ShosA-RecA interaction is sensitive to the presence of ssDNA, implying that ShosTA-mediated abortive infection (Abi) may be triggered by the invading phage DNA. Our studies uncovered the mechanisms of ShosT inducing cell death and ShosA antagonizing the toxic effects of ShosT in anti-phage defense.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.